Teneggi, V., Ng, M., Tan, D. S., Subbiah, V., Weekes, C., Diermayr, V., … Matter, A. (2016). 152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours. In Annals of Oncology (Vol. 27). Elsevier BV. https://doi.org/10.1093/annonc/mdw579.004

Teneggi, V., M. Ng, D. S. Tan, V. Subbiah, C. Weekes, V. Diermayr, K. Ethirajulu, et al. “152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours.” In Annals of Oncology, Vol. 27. Elsevier BV, 2016. https://doi.org/10.1093/annonc/mdw579.004.

Teneggi V, Ng M, Tan DS, Subbiah V, Weekes C, Diermayr V, et al. 152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours. In: Annals of Oncology. Elsevier BV; 2016.

Teneggi, V., et al. “152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours.” Annals of Oncology, vol. 27, no. suppl_9, Elsevier BV, 2016. Crossref, doi:10.1093/annonc/mdw579.004.

Teneggi V, Ng M, Tan DS, Subbiah V, Weekes C, Diermayr V, Ethirajulu K, Yeo P, Chen D, Gan S, Blanchard S, Nellore R, Lee MA, Hill J, Virshup D, Madan B, Matter A. 152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours. Annals of Oncology. Elsevier BV; 2016.